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Ribosome profiling in mouse hippocampus: 
plasticity-induced regulation and bidirectional 
control by TSC2 and FMRP
Annie Hien1,2† , Gemma Molinaro3† , Botao Liu1, Kimberly M. Huber3*  and Joel D. Richter1* 
Abstract 
Background: Mutations in TSC2 are the most common cause of tuberous sclerosis (TSC), a disorder with a high 
incidence of autism and intellectual disability. TSC2 regulates mRNA translation required for group 1 metabotropic 
glutamate receptor-dependent synaptic long-term depression (mGluR-LTD) and behavior, but the identity of mRNAs 
responsive to mGluR-LTD signaling is largely unknown.
Methods: We utilized Tsc2+/− mice as a mouse model of TSC and prepared hippocampal slices from these animals. 
We induced mGluR-LTD synaptic plasticity in slices and processed the samples for RNA-seq and ribosome profiling to 
identify differentially expressed genes in Tsc2+/− and following mGluR-LTD synaptic plasticity.
Results: Ribosome profiling reveals that in Tsc2+/− mouse hippocampal slices, the expression of several mRNAs was 
dysregulated: terminal oligopyrimidine (TOP)-containing mRNAs decreased, while FMRP-binding targets increased. 
Remarkably, we observed the opposite changes of FMRP binding targets in Fmr1−/y hippocampi. In wild-type hip-
pocampus, induction of mGluR-LTD caused rapid changes in the steady-state levels of hundreds of mRNAs, many of 
which are FMRP targets. Moreover, mGluR-LTD failed to promote phosphorylation of eukaryotic elongation factor 2 
(eEF2) in TSC mice, and chemically mimicking phospho-eEF2 with low cycloheximide enhances mGluR-LTD in TSC 
mice.
Conclusion: These results suggest a molecular basis for bidirectional regulation of synaptic plasticity and behavior by 
TSC2 and FMRP. Our study also suggests that altered mGluR-regulated translation elongation contributes to impaired 
synaptic plasticity in Tsc2+/− mice.
© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Tuberous sclerosis (TSC) is an autosomal dominant dis-
order characterized by benign tumor growth in multiple 
organs and neuropsychiatric symptoms. Individuals with 
TSC have an increased incidence of seizures (~ 90%), 
intellectual disability (~ 50%), and autism (~ 50%) [1]. 
Disrupted neuronal circuitry likely underlies many neu-
ropathologies in TSC because individuals with an ana-
tomically normal brain can still present substantial 
developmental delay, intellectual disability, and autism. 
More direct evidence for impaired neuronal connectiv-
ity is derived from mouse models of the disorder, which 
display hyperexcitability, aberrant synaptic plasticity, and 
altered dendritic spine morphology [2, 3]. TSC is caused 
by loss-of-function mutations in TSC1 or TSC2; muta-
tions in TSC2 are more common and are responsible for 
the most severe symptoms. The TSC1/2 proteins heter-
odimerize to form the tuberous sclerosis complex (TSC), 
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a GTPase-activating protein that inhibits Ras homol-
ogy enriched in brain (Rheb) [4, 5]. Rheb activates the 
mechanistic target of rapamycin (mTOR), a kinase that 
forms two biochemically distinct complexes: mTORC1 
and mTORC2 [6]. mTORC1 regulates mRNA transla-
tion primarily via activation of the kinase p70S6K to 
phosphorylate rpS6 and 4E-BP [7–9]. The less-charac-
terized mTORC2 plays a role in actin cytoskeletal reor-
ganization [6]. Complete loss of TSC1 or TSC2 leads to 
excessive mTOR activity, and mutations in other compo-
nents of the mTOR pathway are also linked to autism in 
humans such as PTEN, RHEB, and MTOR [10, 11]. Thus, 
the mTOR pathway forms a highly connected signal-
ing network linked to autism. Although pharmacologi-
cal options are available for the treatment for seizures in 
individuals with TSC, there currently is no effective phar-
macological treatment for the neuropsychiatric symp-
toms of intellectual disability and autism.
The mTOR pathway integrates signaling from various 
inputs to regulate synaptic plasticity and higher cogni-
tive function. One example is metabotropic glutamate 
receptor-mediated long-term depression (mGluR-LTD), 
a form of synaptic plasticity that requires de novo pro-
tein synthesis [12]. The mGluR1/5 agonist dihydroxy-
phenylglycine (DHPG) stimulates group 1 metabotropic 
glutamate receptors to activate the PI3K/AKT/mTOR 
pathway, leading to translation of largely unidenti-
fied mRNAs required for mGluR-LTD [13, 14]. Multi-
ple mouse models of autism, such as TSC and Fragile X 
Syndrome, have altered hippocampal mGluR-dependent 
synaptic plasticity [2, 15–17]. Although experiments 
with rapamycin and inhibitors of protein synthesis sug-
gest that excessive mTORC1-dependent translation 
drives the altered synaptic plasticity phenotype in TSC 
mice, other findings suggest a more complex picture. 
For example, Tsc2+/− mice have reduced hippocampal 
protein synthesis rates instead of the predicted exces-
sive protein synthesis from mTOR hyperactivation [2]. In 
addition, a recent study challenged the role of mTORC1 
in hippocampal mGluR-LTD, arguing that mTORC2 is 
the major regulator of this form of synaptic plasticity [18, 
19] but see [13, 20]. MGluR1/5 signaling can also regulate 
translation factors to suppress global protein synthesis, 
such as phosphorylation of eukaryotic initiation factor 
2 alpha and eukaryotic elongation factor 2 (eEF2), which 
are both necessary for mGluR-LTD [18, 21]. Although 
mGluR1/5 stimulation is known to promote translation 
of specific mRNAs [22], how translation is regulated in 
a transcriptome-wide manner by mGluR1/5 in either the 
normal or TSC brain is unknown.
To study the role of TSC2 in synaptic plasticity, we gen-
erated a germline Tsc2+/− mouse and performed ribo-
some profiling, an unbiased whole transcriptome method 
that determines the number and positions of ribosomes 
on all mRNAs and thus serves as a proxy for protein syn-
thesis [23]. Together with RNA-seq, ribosome profiling 
in wild-type and Tsc2+/− hippocampal slices under basal 
conditions and after induction of mGluR-LTD allows us 
to define posttranscriptional changes in gene expres-
sion in response to synapse activation [12]. We chose 
the Tsc2+/− mouse model, because we strove to capture 
translational dysregulation that arises from TSC2 haplo-
insufficiency as in humans with TSC. This mouse model 
displays excessive mTOR signaling, a well-characterized 
deficient mGluR synaptic plasticity, and alterations in 
social interactions and hippocampal-dependent learn-
ing tasks that are reversed by rapamycin treatment [2, 
24–26]. Using ribosome profiling, we identified changes 
in the Tsc2+/− hippocampus as well as following mGluR-
LTD signaling. We also observed that mGluR1/5 stimula-
tion induces a rapid increase in mRNA levels, and targets 
of Fragile X Mental Retardation Protein (FMRP), an 
RNA-binding protein whose loss causes Fragile X Syn-
drome, are enriched in this group. mGluR stimulation 
also promotes phosphorylation of eukaryotic elongation 
factor (eEF2), which is deficient in Tsc2+/− mice. These 
animals have a reduced mGluR-LTD, and chemically 
mimicking phospho-eEF2 enhances this form of synaptic 
plasticity. Our results suggest a novel pathway of transla-
tional dysregulation in ribosome translocation (polypep-
tide elongation) that may contribute to altered translation 
and synaptic plasticity in TSC mice.
Methods
Animals
Germline Tsc2+/− mice were generated by crossing 
CMV-Cre (B6.C-Tg(CMV-cre)1Cgn/J) (JAX stock num-
ber: 006054) with Tsc2flox mice (JAX Stock number: 
027458). F1 was then bred on the C57BL/6 J background 
to obtain WT and Tsc2+/− mice. Animals were given 
ad libitum access to food and water and reared on a 12-h 
light–dark cycle. All experiments were approved by the 
Institutional Animal Care and Use Committee at Univer-
sity of Texas Southwestern and conducted in accordance 
with the National Institutes of Health Principles of Labo-
ratory Animal Care.
Hippocampal slice preparation
Acute hippocampal brain slices were prepared from P30-
40 wild-type (WT) and Tsc2+/− littermates as described 
previously [27]. Briefly, mice were anesthetized with 
ketamine (125  mg/kg)/xylazine (25  mg/kg) and tran-
scardially perfused with chilled (4 °C) sucrose dissection 
buffer containing the following (in mm): 2.6 KCl, 1.25 
 NaH2PO4, 26  NaHCO3, 0.5  CaCl2, 5  MgCl2, 212 sucrose, 
and 10 dextrose aerated with 95%  O2/5%  CO2. Transverse 
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hippocampal slices (400  µm) were obtained on a Leica 
VT1200S slicer. CA3 was cut off to avoid epileptogenic 
activity induced by DHPG. Slices were recovered for 
3–4 h and maintained at 30 °C in artificial cerebral spinal 
fluid (ACSF) containing the following (in mM): 119 NaCl, 
2.5 KCl, 2  CaCl2, 1  MgCl2, 26  NaHCO3, 1  NaH2PO4, and 
11 D-glucose aerated with 95%  O2/5%  CO2 to pH 7.4. 
Slices were then treated with cycloheximide (100  µg/
ml) in ACSF, 4  °C, snap-frozen on dry ice/EtOH bath, 
and stored at − 80  °C. Alternatively, hippocampal slices 
were treated with DHPG (100  µM) (Tocris) or artificial 
cerebrospinal fluid (ACSF, vehicle) for 5  min. For the 
cycloheximide experiments, hippocampal slices were 
pretreated with 75 nM cycloheximide for 45–60 min. At 
the end of the incubation, CA1 was dissected out, snap-
frozen in a dry ice/ethanol bath and stored at − 80  °C. 
Some hippocampal slices were prepared without remov-
ing CA3 and used for RNA-seq and ribosome profiling 
experiments as indicated below (batches 1–5).
Electrophysiology recordings
For all recordings, slices were submerged and perfused 
with ACSF at 2.5–3.5  ml/min (30 ± 1  °C). Field poten-
tials (FPs) and EPSCs were evoked by stimulation of the 
Schaffer collateral pathway with a concentric bipolar 
tungsten electrode. Field potentials were recorded with 
a glass electrode (1 MΩ) filled with ACSF placed in the 
stratum radiatum of CA1. Test stimuli were delivered 
every 30 s, and a stable baseline was obtained at ∼50% of 
the maximum FP amplitude.
Western Blotting
Western blotting was performed on whole hippocampus 
homogenates or on CA1 hippocampal slices, where indi-
cated, and as previously described [14]. CA1 hippocam-
pal slices were lysed with lysis buffer (50 mm Tris, pH 7.4, 
120  mm NaCl, 50  mm NaF, and 1% Triton X-100, con-
taining Protease Inhibitor Mixture, Sigma #P8340, and 
phosphatase inhibitor mixture 2 and 3, Sigma #P5726 
and #P0040). Samples were homogenized using brief 
(5–10 s) pulses of sonication with an ultrasonic cell dis-
ruptor until lysates were clear. Lysates were then centri-
fuged at 15,700×g for 10  min at 4  °C, the pellets were 
discarded, and protein levels in the supernatant were 
measured using a Pierce BCA kit. After SDS–PAGE, 
proteins were transferred onto PVDF membranes. After 
blocking with 5% BSA in 1 × TBS, 0.05% Tween 20 for 
1  h, membranes were incubated with the following pri-
mary antibodies in blocking buffer overnight at 4 °C: The 
following antibodies were used in this study: S6 Riboso-
mal Protein (Cell Signaling, #2217), Phospho-S6 Riboso-
mal Protein Ser235/236 (Cell Signaling, #4856), Akt (Cell 
Signaling, #9272), Phospho-Akt Ser473 (Cell Signaling, 
#4060), p44/42 MAPK (Erk1/2) (Cell Signaling #9102), 
Phospho-p44/42 MAPK (Erk1/2) Thr202/Tyr204 (Cell 
Signaling, #9101), eEF2 (Cell Signaling, #2332), Phospho-
eEF2 Thr56 (Cell Signaling, #2331), mTOR (Cell Signal-
ing, #2983), Phospho-mTOR Ser2448 (Cell Signaling, 
#2971), 4E-BP1 (Cell Signaling, #9452), Phospho-4E-BP1 
Thr37/46 (Cell Signaling, #9459), RPL4 (Proteintech, 
#11302-1-AP), RPS25 (Sigma, #HPA031801-100UL), 
LARP1 (Proteintech, #13708-1-AP), FMRP (DSHB, 2F5-
1), Glyceraldehyde-3-Phosphate Dehydrogenase (Mil-
lipore, #MAB374), actin (Millipore, #MAB1501). After 
three 10 min washes of 1 × TBS, 0.05% Tween 20, mem-
branes were incubated with the appropriate HRP-conju-
gated secondary antibodies in 5% milk in 1 × TBS, 0.05% 
Tween 20 for 1 h at room temperature. After three 10 min 
washes of 1 × TBS, 0.05% Tween 20, the membranes were 
developed using ECL. For comparison of phosphorylated 
protein levels across conditions or genotypes, immunore-
active phosphorylated protein bands were normalized to 
total protein levels from the same slice homogenates (e.g., 
P-ERK/ERK), each of which was first normalized to load-
ing control (either GAPDH or actin where indicated).
Sample preparation for RiboSeq and RNA‑Seq
Hippocampal slices from six mice were pooled, lysed 
in polysome buffer (as above but with the addition of 
100 ug/mL cycloheximide, 25 U/mL Turbo Dnase I, 1 × 
EDTA-free protease inhibitor, 1% NP-40), and triturated 
with a 25G needle ten times. Following placement on ice 
for 10 min, the lysate was centrifuged 2000g for 10 min at 
4 °C and the supernatant collected and centrifuged again 
for a 20,000g for 10  min at 4  °C. This supernatant was 
collected and the RNA concentration measured using 
the Qubit RNA HS Assay kit (Invitrogen, #Q32852). 
One-fourth of the lysate was saved for RNA-seq libraries 
(~ 1 ug of RNA), and the remainder (~ 3.5 ug) was treated 
with 11.3 ug of RNase A (Ambion, #AM2270) and 1410U 
of Rnase T1 (Thermo Fisher Scientific, #EN0542), which 
corresponds to a ratio of ~ 3ug Rnase A/375U Rnase T1 
per ug of input RNA. The Rnase treatment was carried 
out at 25 °C for 30 min with gentle shaking and the digest 
stopped by placement on ice and the addition of 2.5u L 
of SuperRNaseIn (Invitrogen, #AM2696). The lysate was 
layered over a linear 10–50% sucrose gradient (prepared 
with polysome buffer supplemented with 1  mM DTT 
and 100 ug/mL CHX) and centrifuged at 35,000 rpm for 
2.5 h at 4  °C in a SW41 rotor. The 80S monosome frac-
tions were identified by continuous A260 monitoring and 
pooled for RNA extraction by TRIzol LS. To aid in RNA 
recovery of low concentration samples, 20  ug glycogen 
was added to all precipitation steps. A total of three bio-
logical replicates per genotype and treatment were made 
from hippocampal slices (CA1 enriched, batch 6–8) from 
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Tsc2+/− and their wild-type littermate mice. Wild-type 
slices had a total of eight biological replicates for RiboSeq 
and 7 for RNA-Seq (batch 1–5 from hippocampal slices 
with CA3, batch 6–8 from CA1 enriched).
Library preparation
All RiboSeq libraries were prepared as previously 
described [28]. RiboZero Gold (Illumina, #MRZG12324) 
was used to deplete rRNA for RiboSeq libraries. The puri-
fied 80S monosome mRNA fragments were resolved on 
a 15% Tris-borate urea gel (National Diagnostics, #EC-
833), and ribosome-protected fragments between 26 
and 34 nt were recovered from the gel by the crush–soak 
method overnight in RNA extraction buffer (300  mM 
NaOAc pH5.5 1  mM EDTA 0.25% SDS) at 25  °C with 
constant horizontal rotation. The RNA was then pre-
cipitated, and the purified RNA was dephosphorylated 
with PNK enzyme (NEB, #M0201S) and ligated to pread-
enylated adaptors (IDT) using T4RNL2Tr.K227Q ligase 
(NEB, #M0351L). Reverse transcription (RT) was per-
formed using SuperScript III (Invitrogen, #18080-044) 
in a modified 1X First Strand synthesis buffer without 
 MgCl2 (50  mM Tris–HCl, pH 8.3, 75  mM KCl). Prim-
ers containing a 5  nt barcode and 8  nt unique molecu-
lar identifier (UMI) were used for RT. After RT, the 
RNA was hydrolyzed with a final concentration of 0.1 N 
NaOH for 20 min at 98  °C. The cDNA was resolved on 
a 10% TBU gel, and the 130–140  nt band was selected. 
The cDNA was eluted from crushed gel pieces overnight 
in DNA extraction buffer (300 mM NaCl, 1 mM EDTA, 
10  mM Tris pH8.0) at 25  °C with constant horizontal 
rotation. The cDNA was circularized using CircLigase 
(Epicentre, #CL4115K) and depleted of tRNA and rRNA 
using biotinylated anti-sense probes (IDT) and Dyna-
beads MyOne Streptavidin C1 (Invitrogen, #65001). To 
determine the optimal number of PCR cycles, a test PCR 
was performed using the KAPA library amplification kit 
(Kapa Biosystems, #KK2611). The final PCR product was 
run on an 8% TBE gel, and the 180–190  nt bands were 
selected. The PCR product was eluted overnight in DNA 
extraction buffer as described earlier.
Batch 1–5 RNA-Seq libraries were prepared using 
RiboZero to deplete rRNA and then fragmented with 
2X alkaline fragmentation solution (2  mM EDTA, 
10 mM  Na2CO3, 90 mM  NaHCO3, pH ~ 9.3) at 95 °C for 
15 min to yield ~ 140 nt fragments. The fragmented RNA 
was separated on a 10% TBU gel, and those migrating 
between 100 and 150 nt were selected. RT products were 
separated on a 10% TBU gel, and the 200–250  nt band 
was selected. The final PCR product was run on an 8% 
TBE gel, and the 260-300 bp band was selected. The size 
distribution of the final libraries was confirmed by Frag-
ment Analyzer (UMMS Molecular Biology Core). Batch 
6–8 RNA-Seq libraries were prepared using NEXTflex 
poly(A) beads (Bioo Scientific, #512980) and the NEX-
TFlex Rapid Directional qRNA-Seq kit (Bioo Scien-
tific, # NOVA-5130-03D) according to manufacturer’s 
instructions.
The final libraries were purified using AMPure XP 
beads (Beckman Coulter, #A63880). Purified libraries 
were quantified by qPCR using KAPA Library Quantifica-
tion kit (Kapa Biosystems, #KK4835) and were pooled to 
equimolar ratios. Libraries were sequenced on a NextSeq 
500/550 High Output Kit v2 (Illumina, #FC-404-2005) as 
75 bp single-end runs on a NextSeq500 sequencer.
RiboSeq pipeline, read mapping, and differential 
expression analysis
The individual samples were separated based on 8  nt 
barcodes using custom scripts. Cutadapt (1.7.1) was 
used to remove the adapter (TGG AAT TCT CGG GTG 
CCA AGG AGA TCG GAA GAG CGG TTC AGC AGG 
AAT GCC GAG ACCG). The reads were then uploaded 
to the UMass Bioinformatics Core Dolphin platform 
for mapping (https ://www.umass med.edu/bioco re/
intro ducin g-dolph in/). The reads were quality fil-
tered using Trimmomatic (0.32) and then mapped to 
the rRNA and tRNA reference using bowtie2 (2.1.0). 
The rRNA and tRNA unmapped reads were kept and 
then mapped to mm10 using TopHat2 (2.0.9). Only 
uniquely mapped reads were kept, and PCR duplicates 
were marked based on UMI sequence and a custom 
script. SAMtools (0.019) was used to keep uniquely 
mapped reads without duplicates. For gene-level quan-
tification of RiboSeq, RSEM/1.2.11 was used to align 
cleaned, unique reads to the RefSeq mm10 CDS with 
the first and last 30 nts removed to avoid quantifying 
initiation and termination peaks. For RNA-seq librar-
ies, reads were aligned to the entire mm10 transcrip-
tome. Counts from RSEM were batch-corrected using 
the Combat function in sva (3.24.4). Batch-corrected 
counts were used for DESeq2 (1.26.0) to identify dif-
ferentially expressed genes for RNA and RiboSeq 
libraries. To validate our Tsc2+/−/WT differential 
expression results from Fig.  1, we performed 4990 
random permutations of the sample labels without 
repeating the sample order. Differential expression was 
performed with these randomized sample labels using 
DESeq2 with identical parameters, design formula 
(genotype*treatment), and statistical cutoff (FDR < 0.1) 
as the real samples. The results of the randomizations 
are depicted in the histograms in Additional file  1: 
Fig S1. The majority of the analysis identified zero 
differentially expressed genes, and the randomiza-
tions yielded a mean of 14 DE RNAs and 11 DE RPFs, 
which is similar to the expected false positives from a 
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FDR < 0.1 of our real data (11 false positives/109 DE 
RNAs and ten false positives/99 DE RPF). Normalized 
RNA and RPF counts from DESeq2 were used for gen-
erating plots. anota2seq (1.0.1) was used to calculate 
expression changes in TE (log2FC) using the relative 
log expression (RLE) for normalization.
GO term, GSEA, and gene overlap analysis
GO term enrichment was performed using the R pack-
age clusterProfiler (3.14.0) [29]. For GSEA, mRNAs 
were ranked by their log2FoldChange and p value from 
DESeq2 output. Statistical significance was corrected 




Fig. 1 Ribosome profiling of Tsc2+/− hippocampal slices reveals RNA and RPF dysregulation. a Salient features of TSC and mGluR5 signaling. mTOR 
indirectly receives negative and positive signals from TSC and mGluR5, respectively. mTOR promotes translation required for mGluR5-dependent 
long-term depression (LTD). Dashed and solid lines indicate indirect and direct effects, respectively. The purple stars indicate SFARI autism genes. 
b Schematic depicting the experimental design for RNA-Seq and ribosome profiling from CA1-enriched hippocampal slices of Tsc2+/− and 
wild-type littermate controls. Slices were treated with DHPG (100 µM, 5 min) or artificial cerebrospinal fluid (vehicle) and then processed for 
RNA-Seq and ribosome profiling. Slices from six mice were pooled per genotype and condition, and three biological replicates were performed. 
RPF, ribosome-protected fragment. c Normalized count plots of RNA and RPF levels for Tsc2 are shown (Wald-test for genotype comparison with 
BH correction. RNA: log2FC − 0.52, padj < 7.4e−32; RPF log2FC − 0.70, padj < 2.4e−22) d, e Heat maps of mRNAs (d) and RPFs (e) altered in Tsc2+/− 
compared to WT under basal conditions. Relative gene expression is shown, and each column represents a biological replicate (n = 3) for RNA 
(DE = 109, FDR < 0.1) and RPFs (DE = 99, FDR < 0.1). f GO term enrichment of upregulated RPFs in Tsc2+/− (padj < 0.05)
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were considered enriched. Gene overlap analysis was 
performed using the R package GeneOverlap (1.22.0). 
The genes past filtering from DE analysis were used as 
the background.
Transcript feature analysis
Gene features were obtained from the UCSC Genome 
Browser using RefSeq annotations. For downstream 
transcript analysis, the most abundant isoform from the 
RSEM output of the RNA-Seq libraries was selected. 
ViennaRNA/RNAFold (2.1.6 h) was used to calculate the 
minimal free energy of the 5′UTR.
Hippocampal TE calculation and rolling mean plots
The average CA1 translational efficiency (TE) was cal-
culated by taking the ratio of RPF to RNA reads per 
kilobase per million mapped reads (RPKM) from three 
wild-type basal samples aligned to the mm10 CDS ref-
erence without the initiation and termination peak. For 
consistent TE calculations, mapping to the CDS for RPF 
and RNA was used, and transcripts longer than 300  nt 
and RPKM > 5 were included.
Quantification and statistical analysis
An unpaired Wilcoxon rank-sum test with Bonfer-
roni correction was used to compare means between 
groups unless indicated otherwise in the text and fig-
ures. A one-tailed Kolmogorov–Smirnov test was used 
as shown in Fig.  2c. An unpaired t test was used for 
quantification of western blots in Fig. 3c and Additional 
file  1: Fig S2B, C. Western blot results in Fig.  6a–c 
were analyzed with a two-way, repeated-measures 
ANOVA. Factors are DHPG treatment and genotype, 
and repeated measures are basal and DHPG levels in 
the same mouse. n = # mice. Post hoc Sidak’s multiple 
comparison test was performed to determine statisti-
cal significance for specific comparisons, reported in 
the figure. For analysis of LTD results in Fig.  6f, g, we 
performed a linear mixed-effects model (LMM) statis-
tic, whereby the variability due to random effects (ani-




Fig. 2 Dysregulation of TOP mRNAs in Tsc2+/−. a Schematic depicting mTOR control of translation. mTOR controls mRNA-specific translation 
via 5′ terminal oligopyrimidine (TOP) motifs or long, structured 5′UTRs. mTOR controls global initiation and elongation via phosphorylation/
dephosphorylation of 4E-BP, rpS6, and eEF2. b mRNA, RPF, and translation efficiency (TE) expression changes (Tsc2+/−/WT log2FC) for TOP mRNAs 
(n = 68). Wilcoxon rank-sum test with correction by Bonferroni method. c Density plots of the hippocampal TE for the up and down RNA (left) and 
RPF (right) groups in Tsc2+/−/WT compared to all genes (one-tailed Kolmogorov–Smirnov test). The hippocampal TE is calculated from the average 
of wild-type basal slices as the ratio of RPF to RNA. d Schematic depiction of how loss of Tsc2 could affect translation of lowly and highly translated 
mRNAs
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measurement of genotype and/or treatment effects 
[30]. Mixed-effects models were fitted using IBM 
SPSS package. Fixed factors were genotype, treatment, 
genotype*treatment; repeated/random effects were 
slices nested within subject (mouse).
Code availability
Custom scripts for generating plots will be available 
upon request to the lead contact.
Results
Translational profiling of the TSC hippocampus
The GTPase activating protein tuberous sclerosis com-
plex (TSC) is an upstream but indirect repressor of 
mTOR, a kinase which forms the multi-subunit com-
plex mTORC1 to stimulate translation in response to a 
number of signaling inputs including activated group 
I metabotropic glutamate receptors (e.g., mGluR5). 
mGluR5 activation leads to long-term depression (LTD), 




Fig. 3 FMRP binding targets are regulated by TSC and FMRP in opposing directions. a Empirical cumulative distribution function (ECDF) of RNA 
(left), RPF (middle), and TE (right) expression changes in Tsc2+/−/WT (log2FC) of FMRP binding targets compared to nontarget mRNAs. FMRP 
binding targets are stratified into three groups based on binding stringency. Wilcoxon rank-sum test with correction by Bonferroni method. p 
values are indicated in the plot legend. b ECDF of RNA (left), RPF (middle), and TE (right) expression changes in Fmr1−/y/WT (log2FC) of FMRP 
targets compared to nontarget mRNAs. Data of hippocampal slices of Fmr1−/y mice from Shah et al. [76]. Wilcoxon rank-sum test with correction by 
Bonferroni method. p values are indicated in the plot legend. c The levels of FMRP as determined by western blots of fresh, whole hippocampus 
from wild-type and Tsc2+/− littermate. n = 5 animals, ns nonsignificant, unpaired t test
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frequently examined at hippocampal Schafer collateral-
CA1 synapses (Fig.  1a) [12]. TSC is a neurodevelop-
mental disorder characterized by autism, epilepsy, and 
intellectual disability, and to study the role of TSC2 in 
synaptic plasticity, we generated mice lacking one copy of 
the Tsc2 gene, which will henceforth be referred to as the 
Tsc2+/− mouse.
To detect subtle changes in translation, we turned to 
ribosome profiling, a high-resolution and unbiased whole 
transcriptome method for determining the number and 
positions of ribosomes on mRNA. When combined 
with RNA-seq, the ratio of ribosome occupancy over 
input mRNA yields translational efficiency (TE) [23]. 
Although TE is often used as a proxy for protein synthe-
sis, changes in TE may not always reflect protein output 
when ribosome elongation or mRNA levels are altered. 
Hippocampal slices, some of which were treated with 
dihydroxyphenylglycine (DHPG) for 5  min to induce 
LTD, were lysed in the presence of cycloheximide to 
prevent ribosome run-off, digested with RNase, and the 
80S monomers containing ~ 30  nt ribosome-protected 
fragments (RPFs) were collected by ultracentrifugation 
(Fig.  1b). The isolated RPFs were appended with prim-
ers for library construction and sequencing (> 10 million 
uniquely mapped reads; libraries were strongly correlated 
with each other; Pearson’s R > 0.99).
Tsc2 was the top differentially expressed mRNA at 
both the RNA and RPF levels, confirming the validity of 
our approach (Fig. 1c). Figure 1d, e shows heat maps of 
the RNAs and RPFs, respectively, from the hippocampal 
slices of the Tsc2+/− mice and their littermate controls 
under basal (unstimulated) conditions that pass a sig-
nificance cutoff of FDR < 0.1. The differentially expressed 
(DE) RNAs and RPFs altered in Tsc2+/− had little overlap 
with each other (n = 5). The ratio of RPF to RNA yields 
translational efficiency (TE), but because changes in TE 
do not distinguish between RPF and RNA effects and 
because few RNAs passed statistical cutoff for changes 
in TE (log2FC), we considered RNA and RPF changes 
separately.
We observed enrichment for terms related to the 
GABA-receptor complex, mitochondrial membrane, 
and myelin sheath for RPFs that were Upregulated in 
the Tsc2+/− brain (Fig. 1f, see Additional file 2: Table S1). 
No GO terms were enriched in the downregulated RPF 
group, likely due to the small number of genes. An altered 
excitatory/inhibitory balance is frequently observed 
in ASD, and the increased translation of GABA-A-
related proteins may be a compensatory response to the 
increased hyperexcitability observed in Tsc2+/− mice 
[31–35]. Altered translation of mitochondrial membrane 
proteins is consistent with the role of mTOR-dependent 
translational control of mitochondrial-related mRNAs 
and reports of mitochondrial dysfunction in Tsc2-defi-
cient cultured neurons [36, 37]. The abnormalities in 
myelination in TSC patients and function of TSC/mTOR 
in myelination and function of oligodendrocytes [38, 
39] may be due to translational control of myelin sheath 
proteins.
Dysregulation of 5′ terminal oligopyrimidine (TOP) mRNAs
The major downstream substrate of TSC is mTOR, which 
controls specific and global translation (Fig. 2a). mRNAs 
that contain a 5′ terminal oligopyrimidine motif (TOP), 
which generally encode components of the translational 
machinery, and mRNAs with long, structured 5′ UTRs 
are especially sensitive to mTOR regulation [40–43]. 
TSC/mTOR also regulates general translation through 
phosphorylation/dephosphorylation events such as those 
that occur on 4E-BP, eIF4B, rpS6, and eEF2 [43–46]. 
Elevated mTOR signaling contributes to various behav-
ioral and synaptic plasticity phenotypes in the brains 
of TSC mice as evidenced by their rescue by treatment 
with the mTOR inhibitor rapamycin [2, 24]. We found 
that the TOP mRNAs had mildly increased RPFs, but as 
a group, they had increased TE that is primarily driven 
by decreased RNA levels (Fig. 2b). mTOR can also pro-
mote initiation of non-TOP mRNAs that have long, 
structured 5′UTRs via eIF4E and eIF4A [40]. However, 
we find no difference in the 5′UTR lengths or predicted 
secondary structures in the up- and downregulated RPFs 
(Additional file  1: Fig S2A). To assess whether signaling 
events usually associated with mTOR activation occur in 
Tsc2+/− hippocampus, we examined levels of phospho-
rylated mTOR, rpS6, and 4E-BP1. We also performed 
western blots for two TOP mRNAs, RPL4 AND RPS25, 
as well as LARP1, a TOP RNA-binding protein [47, 48]. 
Changes in the basal levels of these proteins are unde-
tectable in the TSC hippocampus, and there is only a 
trend toward increases in phospho-4E-BP1 (Additional 
file 1: Fig S2B, C), similar to previous reports [35].
Because we did not identify specific mRNA features 
in the mRNAs and RPFs dysregulated in Tsc2+/− mice, 
we wondered whether the mRNA-specific dysregulation 
may arise by altered global protein synthesis put forward 
by the “ribosome concentration” hypothesis from Mills 
and Green [49]. Their “ribosome concentration” hypothe-
sis proposed that mRNAs with different rates of initiation 
respond bidirectionally to subtle changes in global trans-
lations from altered ribosome levels. Although we do not 
have evidence of altered mTORC1-rpS6 signaling or ribo-
some concentrations in Tsc2+/− mice, we used this model 
as an intellectual framework for interpreting our results. 
We approximated initiation by calculating TE from wild-
type basal slices, which will be referred to as hippocam-
pal TE. The Up RNAs in Tsc2+/− had a low hippocampal 
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TE compared to all (Fig.  2c, left). We find that mRNAs 
with Down RPFs in Tsc2+/− had a low hippocampal TE, 
and the Up RPFs had a high hippocampal TE compared 
to all (Fig. 2c, right). These results suggest that in Tsc2+/− 
mice, poorly translated mRNAs are reduced even further, 
while highly translated mRNAs become more robustly 
translated (Fig. 2d). Finally, Additional file 1: Figure S1D 
shows transcript features that correlate with hippocam-
pal TE. Consistent with another study, hippocampal TE 
is correlated with GC content of the CDS, 3′UTR, and 
5′UTR and also CDS length [50].
FMRP binding targets are altered in opposite directions 
in TSC and FXS mice
Loss of the RNA-binding protein Fragile X Mental Retar-
dation Protein (FMRP) leads to Fragile X Syndrome 
(FXS). FMRP and TSC2 bidirectionally regulate mGluR-
LTD and behavior, suggesting they coregulate similar 
mRNAs. In support of this, a combined TSC/FXS mouse 
rescues deficits in synaptic plasticity and learning to 
wild-type levels compared to the single mouse mutants 
[2]. Given the rescue paradigm of the FXS and TSC 
mouse, we determined whether FMRP targets are altered 
in Tsc2+/− mice. We used a list of FMRP targets identified 
by CLIP (cross-link and immunoprecipitation) in CA1 
pyramidal neurons, where FMRP targets were stratified 
into three groups based on binding strength: stringent 
(n = 327), high (n = 938), and low (n = 1330) binding tar-
gets [51]. FMRP targets are enriched (p < 5.3e−8) in the 
mRNAs altered in TSC (from Fig.  1d), and as a group, 
they have decreased TE that is driven by increased RNA 
levels that correlate with stringency of FMRP binding 
(Fig. 3a). FMRP targets have no change in RPFs in TSC 
(Fig.  3a, middle). Interestingly, the FMRP targets are 
decreased in the FXS mouse (Fmr1−/y), which is also 
correlated with stringency of FMRP binding (Fig.  3b) 
[51–54]. Because FMRP binding targets were dysregu-
lated in Tsc2+/−, we determined whether FMRP protein 
levels were altered in Tsc2+/−. FMRP levels were unal-
tered in Tsc2+/− (Fig.  3c), suggesting that the increased 
RNA levels of FMRP targets in Tsc2+/− mice are not 
caused by altered FMRP levels. This bidirectional change 
in FMRP target mRNAs could be linked to the TSC/FXS 
mouse rescue paradigm and reveals a complex interac-
tion between TSC2 and FMRP in steady-state regulation 
of mRNAs in the hippocampus.
DHPG‑induced mGluR signaling induces a rapid RNA 
and translational response
mGluR-LTD is regulated by TSC, so to determine the 
identity of mGluR-stimulated translation of specific 
RNAs during LTD, we performed ribosome profiling 
and RNA-seq on hippocampal slices following 5  min 
of DHPG treatment [12, 18, 22]. Figure  4a, b shows 
that RNA (DE = 241, FDR < 0.01) and RPF (DE = 212, 
FDR < 0.05) levels undergo rapid changes in response 
to the mGluR1/5 agonist DHPG. DHPG-respon-
sive RNAs and RPFs largely did not overlap (n = 5). 
Our DHPG-responsive translational changes in area 
CA1 do not overlap with those identified by poly-
some RNA-seq in cultured cortical neurons, which 
we attribute to different sample types and method-
ologies [21]. Gene set enrichment analysis reveals 
that GO terms related to G protein-coupled receptor 
activity, synaptic membranes, and the endoplasmic-
reticulum membrane are enriched in the upregulated 
RNA and RPFs, and helicase activity is enriched in the 
downregulated RNAs and RPFs (Additional file  1: Fig 
S3A, B, Additional file  3: Table  S2). Some GO terms 
are unique to the RNA or RPF changes. For example, 
the RNAs upregulated following DHPG are enriched 
for transcription-related functions, and the DHPG 
translational response is enriched for terms related 
to the lysosome. Some examples of DHPG-responsive 
mRNAs and RPFs that are high confidence SFARI 
autism genes (https ://gene.sfari .org, score 1 or 2) are 
shown in Fig.  4c for Shank3, Dlg4, and Ache. Dlg4 
mRNA encodes PSD-95, which has increased mRNA 
and protein levels following DHPG-mGluR signal-
ing [55]. Nrsn1 mRNA encodes a neuron-enriched 
regulator of vesicle transport, which is translation-
ally repressed 5  min after a hippocampus-dependent 
learning task [56]. Translational repression of Nrsn1 
mRNA during learning may be a requirement for this 
cognitive process as evidenced by the observation 
that its overexpression leads to deficits in object loca-
tion and contextual fear memory. Because we did not 
observe immediate early genes (c-fos, Arc, and Egr1) in 
our list of differentially expressed RNAs, we infer that 
the rapid changes in RNA levels are likely due to alter-
ations in RNA destruction and not transcription.
Because FMRP is regulated by and required for 
mGluR1/5 signaling to translation [57–60], we deter-
mined whether FMRP mRNA targets are responsive 
to this form of synaptic plasticity. FMRP binding tar-
gets are enriched in the DHPG-responsive DE RNAs 
(p < 1.8e−44) and RPFs (p < 5.0e−9). As a group, the 
FMRP targets have increased RNA levels follow-
ing mGluR signaling that correlate with stringency 
of FMRP binding (Fig.  4d, left). FMRP targets have 
decreased RPFs following synaptic stimulation, and an 
overall decrease in TE that correlates with FMRP bind-
ing stringency (Fig.  4d, middle and right). Therefore, 
mGluR stimulation regulates translation and RNA lev-
els of FMRP target mRNAs.
Page 10 of 18Hien et al. Molecular Autism           (2020) 11:78 
mGluR‑induced translational dysregulation in TSC
Tsc2+/− mice have deficient mGluR-LTD, so we deter-
mined whether the RNA and translational response after 
DHPG is altered. We lacked sufficient statistical power 
to detect genotype-dependent alterations in the DHPG 
response in Tsc2+/− slices with their littermate con-
trols. Instead, we compared the genes altered in Tsc2+/− 
(Fig. 1d, e) and the DHPG-responsive genes in wild type 
(Fig.  4a, b) and found a statistically significant overlap 
for the RNAs (n = 23, p < 4.3e−21) and RPFs (n = 20, 
p < 3.8e−18) (Fig.  5a, b; Additional file  4). Interestingly, 
16 of the 23 RNAs that overlap between Tsc2+/− and 
mGluR1/5-stimulated are FMRP mRNA targets (e.g., 
Kif5a, Snph, Nisch, and Slc25a23). No GO terms were 
enriched in the overlapping list, likely due to the small 
number of genes. Heat maps of the overlapped mRNAs 
and RPFs in Fig.  4a, b show that most of the upregu-
lated mRNAs and RPFs in unstimulated Tsc2+/− slices 
appear to have a deficient DHPG response compared 
to wild-type slices (Fig.  5c, d). Our results suggest that 
some mRNAs and RPFs that are elevated in unstimulated 
Tsc2+/− slices cannot respond to DHPG.
Signaling to eukaryotic elongation factor 2 is altered 
in the Tsc2+/− hippocampus
The sequencing results of the Tsc2+/− slices under basal 
and DHPG conditions suggest there is a deficiency in the 
ability of DHPG to regulate translation in the Tsc2+/− 
mice. To determine whether mGluR1/5 signaling to 
translational control was altered in Tsc2+/−, hippocampal 
slices were treated with DHPG followed by western blot-
ting for several well-established downstream substrates 
of mGluR activation. Figure 6a, b shows that under basal 
conditions, phosphorylated (phospho) ERK and AKT 




Fig. 4 mGluR signaling induces rapid RNA and RPF changes in wild-type hippocampal slices. a, b Heat maps of mRNAs and RPFs that are 
responsive to DHPG (100 µM, 5 min) in wild-type hippocampal slices. Relative gene expression is shown; each column represents a biological 
replicate (n = 7 for RNA-Seq, n = 8 for ribosome profiling), differentially expressed RNA (n = 241, FDR < 0.01) and RPFs (n = 212, FDR < 0.05). c 
Examples of DHPG-responsive mRNAs (top) or RPFs (bottom) are shown with normalized RNA and RPF counts from DESeq2. p values are from the 
output of DESeq2 analysis (Wald-test with BH correction). d Empirical cumulative distribution function (ECDF) of RNA (left), RPF (middle), and TE 
(right) expression changes in DHPG/Basal (log2FC) of FMRP binding targets compared to nontarget mRNAs. FMRP binding targets are stratified into 
three groups based on binding stringency. Wilcoxon rank-sum test with correction by Bonferroni method. p values are indicated in the plot legend




Fig. 5 Some mRNAs altered in unstimulated Tsc2+/− slices do not respond to DHPG-mGluR signaling. a, b Venn diagrams showing overlap 
between Tsc2+/− dysregulated RNAs and DHPG-responsive RNAs (a) and Tsc2+/− dysregulated RPFs and DHPG-responsive RPFs (b). Gene overlap 
test was performed using Fisher’s exact test and a background size of expressed RNAs used in DE analysis. c, d Heat maps of mRNAs (c) and RPFs (d) 
that overlap from (a) and (b). Relative gene expression is shown, and each column represents a biological replicate of littermates (n = 3)
(See figure on next page.)
Fig. 6 Deficient mGluR1/5-regulated signaling to translation elongation suppresses mGluR-LTD in Tsc2+/− mice. a–c The levels of phosphorylated 
(P) and total (T) ERK (a), AKT (b), and eEF2 (c) in CA1-enriched hippocampal slices from wild-type and Tsc2+/− mouse littermates as determined 
by western blots under basal or DHPG-treatment condition (100 µM; 5 min). *p < 0.05; **p < 0.01; ***p < 0.001; 2 way ANOVA, post hoc Sidak’s test, 
n = 11–19 mice/genotype, 4–5 slices per drug condition/mouse. Asterisks below brackets indicate an effect of DHPG on phosphoprotein levels 
within genotype. Asterisks above brackets indicate effects between genotypes. d Schematic depicting that global slowing of ribosome movement 
through eEF2 phosphorylation or low dose cycloheximide (CHX) may promote protein synthesis of lowly translated mRNAs while inhibiting 
highly translated mRNAs. e Empirical cumulative distribution function (ECDF) plot of hippocampal TE for the Up and Down RNAs (left) and RPFs 
(middle) in DHPG/basal compared to all genes. Right: ECDF plot of hippocampal TE for FMRP binding targets compared to non-target mRNAs. 
FMRP binding targets are stratified into three groups based on binding stringency. Wilcoxon rank-sum test with correction by Bonferroni method. p 
values are indicated in the plot legend. f Left: Time course demonstrating that brief DHPG application (100 µM; 5 min) induces long-term synaptic 
depression (LTD) of field (f ) EPSP slopes in WT hippocampal slices that is unaffected by low doses of cycloheximide (45–60 min pretreatment, 
75 nM; n = 12 and 15 slices; 6–7 mice/condition). Right: In Tsc2+/− mice pretreatment with low-dose cycloheximide enhances LTD magnitude 
(n = 10 and 15 slices; 7 mice/condition). Plotted are group averages of fEPSP slope (mean ± SEM) normalized to pre-DHPG baseline as a function of 
time. Inset: Example fEPSP from baseline and during LTD (55–60 min post DHPG). Scale = 0.5 mV/10 ms. g LTD magnitude, measured at 55–60 min 
post-DHPG application in vehicle and cycloheximide in each genotype. There is a significant interaction between cycloheximide and Tsc2 genotype 
(F(1,47) = 5.197, p < 0.05; LMM). With post hoc pairwise comparisons, there is a strong trend for cycloheximide to enhance LTD in Tsc2+/− mice (veh: 
83 ± 2% of baseline; cycloheximide; 75 ± 5%; n = 15 and ten slices from four mice/treatment; F(1,23) = 5.445, p = 0.058; LMM) but not WT mice 
(veh: 74 ± 2% of baseline; cycloheximide; 77 ± 3%; n = 11 and 15 slices from 6 and 5 mice, respectively/treatment; F(1,24) = 3.819, p = 0.14; LMM). 
In vehicle, LTD is reduced in Tsc2+/− mice in comparison with WT, but not in low-dose cycloheximide. (*p < 0.05; **p < 0.01). h Schematic showing 
DHPG induction of eEF2 phosphorylation in hippocampal slices. In WT slices, DHPG leads to increased levels of phospho-eEF2 through signaling 
to eEF2K, which presumably slows ribosome transit and promotes expression of lowly translated mRNAs required for mGluR-LTD, such as FMRP 
binding targets. In TSC slices, levels of phospho-eEF2 are elevated basally and correlate with increased mRNA abundance of FMRP binding targets. 
DHPG treatment does not further increase eEF2 phosphorylation, and Tsc2+/− slices may have excessive ribosome transit during mGluR signaling 
that contributes to deficient mGluR-LTD.






Page 13 of 18Hien et al. Molecular Autism           (2020) 11:78  
to DHPG treatment, phospho-ERK levels were similarly 
elevated in WT and Tsc2+/− slices, consistent with other 
observations [2, 42]. DHPG did not induce phospho-
Akt in either WT or Tsc2+/− slices. Because both mTOR 
signaling and mGluR5 signaling regulate phosphoryla-
tion of eukaryotic elongation factor 2 (eEF2), we deter-
mined whether signaling to eEF2 could be altered. In 
wild-type slices, DHPG treatment robustly induces eEF2 
phosphorylation (Fig.  6c). Surprisingly, Tsc2+/− slices 
have elevated phospho-eEF2 basally, and DHPG treat-
ment fails to induce eEF2 phosphorylation. Total levels 
of eEF2 are unchanged in Tsc2+/− at basal (106 ± 6% of 
WT; n = 19 mice; n.s.; 2way ANOVA, post hoc Sidak’s 
test) and following DHPG treatment (WT 101.7 ± 8.02%, 
Tsc2+/− 114.4 ± 9.69%, n = 19, n.s.; 2way ANOVA, post 
hoc Sidak’s test).
eEF2 is a GTP-dependent elongation factor that pro-
motes transfer of peptidyl-tRNAs from the A to P site of 
the ribosome. Phosphorylation of eEF2 on threonine 56 
prevents it from binding to ribosomes, leading to inhibi-
tion of translation elongation [61]. Somewhat counter-
intuitively, eEF2 kinase and its phosphorylation of eEF2 
are necessary for mGluR-induced synthesis of proteins 
required for LTD [18]. Global inhibition of translation 
elongation, such as through phospho-eEF2 or cyclohex-
imide (a chemical inhibitor of ribosome translocation), 
may promote synthesis of poorly translated mRNAs 
by liberating rate-limiting translation factors (Fig.  6d) 
[18, 62, 63]. Thus, we determined whether the mRNAs 
responsive to mGluR-LTD signaling are enriched for 
poorly translated mRNAs by using hippocampal transla-
tion efficiency as described earlier. We find that the Up 
RNA group after DHPG treatment has low basal trans-
lation efficiency compared to unchanged mRNAs and 
the Down mRNA group has high basal translation effi-
ciency (Fig.  6e, left). For the translational response, the 
Up RPF group after DHPG-mGluR signaling has high 
basal translation efficiency compared to other mRNAs, 
whereas the Down RPF group had the same translation 
efficiency as the unchanged mRNAs (Fig.  6e, middle). 
Because DHPG-mGluR signaling may reduce ribosome 
translocation via phospho-eEF2, it is possible that at least 
some of the mRNAs with increased RPFs are associated 
with stalled ribosomes, in which case they would have 
decreased translation. Because FMRP binding targets 
are enriched in the DHPG-mGluR-responsive Up mRNA 
group, we predicted that FMRP targets are also lowly 
translated in the hippocampus. Indeed, FMRP binding 
targets have low basal translation efficiency compared 
to nontargets (Fig.  6e, right). Interestingly, the strength 
of FMRP binding negatively correlates with basal trans-
lation efficiency where the most stringent FMRP targets 
have lower basal translation efficiency compared to the 
low- and high-stringency groups. Taken together, these 
observations suggest that mGluR5 signaling increases 
expression of mRNAs that are lowly translated, such as 
FMRP binding targets.
Because Tsc2+/− slices have a deficient phospho-eEF2 
response to DHPG treatment, we hypothesized that ribo-
some elongation is excessive during mGluR signaling in 
Tsc2+/− and may contribute to deficient mGluR-LTD. 
We used a low concentrations of cycloheximide (75 nM), 
which inhibits ribosome elongation by binding to the 
E-site of the ribosome to prevent eEF2-mediated translo-
cation [64]. This concentration of cycloheximide restored 
mGluR-LTD in eEF2K knockout mice without affecting 
mGluR-LTD in WT mice [18]. We induced mGluR-LTD 
with DHPG in hippocampal slices and tested the effects 
of low-dose cycloheximide (75  nM) to inhibit ribosome 
elongation. While there were no main effects of genotype 
or treatment overall on LTD magnitude, we observed a 
significant interaction of genotype*treatment (Fig.  6f, 
g). With post hoc pairwise comparisons, there was a 
strong trend for cycloheximide to enhance mGluR-LTD 
in Tsc2+/− (veh: 83 ± 2% of baseline; cycloheximide; 
75 ± 5%) but not WT mice (veh: 74 ± 2% of baseline; 
cycloheximide; 77 ± 3%). In vehicle, mGluR-LTD in 
Tsc2+/− was less than WT as previously reported [2]. Our 
data suggest that the deficiency of mGluR1/5 induced 
P-eEF2 and suppression of translation elongation in 
Tsc2+/ mice limits LTD magnitude and this can be rein-
stated by pharmacological inhibition of ribosome elonga-
tion (Fig. 6h).
Discussion
Using ribosome profiling and RNA-seq, we identified 
changes in ribosome footprint number and RNA levels in 
Tsc2+/− hippocampal slices and following mGluR-LTD. 
Our experimental design captures changes from multiple 
cell types, which is reflective of the tissue complexity of 
the hippocampus. We found translation of myelin-related 
mRNAs increased in Tsc2+/− mice, which are predomi-
nantly found in oligodendrocytes. The tissue complex-
ity may explain why we did not capture translation of 
known DHPG-induced mRNAs Arc and Map1b, which 
are translated following DHPG treatment in dendrites of 
excitatory neurons [22, 65].
In complete loss of TSC1 or TSC2 models, there is 
clearly excessive mTOR activity that leads to widespread 
changes in translation [66]. However, mTOR hyperactiva-
tion is not always as obvious in Tsc1 and Tsc2 heterozy-
gote models in the brain [35]. Using a Tsc2+/− model, we 
do not observe signs of mTOR hyperactivation by west-
ern blot of phosphorylated mTOR, 4E-BP1, and rpS6 
in the hippocampus. Instead, we find evidence of dis-
rupted global mRNA translation by increased TE of TOP 
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mRNAs and elevated levels of phosphorylated eEF2. The 
TOP mRNAs, the most well-studied TSC/mTOR trans-
lational targets, have increased TE from predominantly 
decreased RNA and increased RPF levels. The decreased 
RNA levels of the TOP mRNAs are surprising, given that 
one predicts increased expression of TOP mRNAs from 
mTOR hyperactivity from loss of TSC2. There could be 
two possibilities to explain this observation. This may be 
an example of translational buffering to maintain homeo-
stasis of proteins encoded by TOP mRNAs, where RNA 
levels decrease to offset the increase in ribosome occu-
pancy [67, 68]. Alternatively, the decreased RNA levels 
of TOP mRNAs may be reflective of the altered signal-
ing to phospho-eEF2, which is increased and opposite of 
the direction that is predicted by activation of mTORC1-
S6K-eEF2K signaling in Tsc2+/− [45, 46]. The increased 
in basal phosphorylated eEF2 in Tsc2+/−mice may occur 
via other effectors to eEF2K, such as increased intracel-
lular Ca2 + and mGluR1/5 signaling [18, 69]. Our finding 
of increased basal levels of phospho-eEF2 is consistent 
with the observation of decreased protein synthesis rates 
in hippocampal slices of Tsc2+/− mice [2]. Our study sug-
gests a more complex role of translational dysregulation 
in the Tsc2+/− hippocampus outside of simple mTORC1-
rpS6 hyperactivation. Given the many downstream sub-
strates of mTOR, it is possible that some of the mRNA 
and translational alterations observed in Tsc2+/− are 
through mTORC1-dependent processes outside of trans-
lation (e.g., autophagy, lipogenesis) or mTORC2. The 
small sample size for the Tsc2 genotype comparison is 
a limitation to our sequencing analysis, which has low 
power to identify differences from lowly expressed genes 
and small effect changes frequently observed in the brain 
and neuropsychiatric disorders. Our results do not rule 
out more dramatic, cell-type specific arising from Tsc2 
haploinsufficiency, such as in excitatory neurons. These 
results also highlight the importance of maintaining 
appropriate gene dosage in modeling TSC and other 
mTORopathies such as PTEN, where only one allele is 
usually mutated in patients.
Because Tsc2+/− mice have decreased protein synthesis 
in the hippocampus and DHPG-mGluR1/5 signaling can 
activate near global regulators of translation, and we used 
the “ribosome concentration” hypothesis as an intellec-
tual framework for interpreting our results. This model 
was originally proposed to explain the seemingly mRNA-
specific effects arising from ribosomopathies, a group of 
disorders with mutations in ribosomal proteins that man-
ifest with cell-type-specific features. Using mathemati-
cal modeling and assuming initiation as the rate-limiting 
step of translation, the “ribosome concentration” hypoth-
esis predicts that efficiently and inefficiently translated 
mRNAs respond bidirectionally to global decreases in 
translation arising from reduced levels of ribosomes, and 
recent experimental evidence from yeast and hematopoi-
etic cells supports this hypothesis, albeit in a direction 
opposite of originally predicted [70, 71]. Here, we observe 
a trend where in Tsc2+/− mice, inefficiently translated 
mRNAs have decreased translation and efficiently trans-
lated mRNAs have increased translation (Fig.  2e). Sur-
prisingly, during DHPG-mGluR1/5 signaling, the degree 
of translation efficiency correlates more with RNA-level 
changes rather than translation, and FMRP binding tar-
gets have low translation efficiency compared to all genes 
(Fig. 6e, left). The factors that regulate this phenomenon 
in Tsc2+/− mice and DHPG-mGluR1/5 signaling remain 
unknown.
RNA-seq reveals that mGluR activation induces a rapid 
response in both increased and decreased mRNA levels. 
Because translation is often linked to RNA stabilization/
destabilization, this mGluR response could be linked to 
this process [72]. The decrease in specific mRNAs may be 
the result of heightened rates of degradation, which could 
be the consequence of mGluR-dependent upregulation 
of microRNAs [73]. For mRNAs that increase, there may 
be a constant rate of mRNA turnover in hippocampal tis-
sue, and mGluR activation could lead to mRNA stabili-
zation through regulation of translation or microRNA 
dissociation [60]. The DHPG-mGluR-responsive mRNAs 
are highly enriched for FMRP targets and genes encod-
ing synaptic proteins. For example, our study and that 
of Zalfa et  al. [55] found that levels of PSD-95 mRNA 
(Dlg4), an FMRP target, increase after mGluR activation 
in cultured neurons and are regulated by interaction with 
a microRNA [60]. Several recent studies have supported 
the role of FMRP in modulating stability of its targets 
through  N6-methyladenosine modification of the mRNA 
and codon optimality [54, 74]. The observation that 
DHPG results in decreased RPFs and TE on FMRP tar-
get mRNAs suggests they have reduced translation. This 
would be a surprising finding based on previous work 
that DHPG rapidly stimulates the synthesis of proteins 
encoded by FMRP target mRNAs such as Map1b, Arc, 
EF1a, and PSD-95 [22, 60, 65, 75]. Therefore, decreased 
RPF and TE may not always indicate reduced synthesis 
of protein. Some evidence indicates that FMRP stalls or 
slows ribosome translocation, and mGluR stimulation 
regulates translation elongation through FMRP and eEF2 
phosphorylation [18, 59, 76, 77]. Thus, for some mRNAs, 
the observed decrease in RPF or TE on FMRP target 
mRNAs in response to DHPG may be a consequence of 
enhanced ribosome movement that reflects increased 
protein synthesis.
Recent work has revealed regulation of translational 
elongation as critical for multiple forms of protein-
synthesis-dependent synaptic plasticity, including 
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mGluR-LTD signaling [18, 78–80]. DHPG-induced 
mGluR1/5 signaling via ERK and AKT is normal in the 
Tsc2+/− hippocampus, which mainly feeds into regu-
lation of translation initiation [81]. Instead, signaling 
to ribosome translocation (polypeptide elongation) 
is altered in Tsc2+/− and a low-dose cycloheximide 
enhances mGluR-LTD in these mice. Increased levels of 
phospho-eEF2 and low-dose cycloheximide have previ-
ously been shown to paradoxically increase translation 
of specific mRNAs, such as Arc and alpha-CAMKII, 
despite globally inhibiting protein synthesis [18, 80]. Fur-
thermore, we find evidence for a mechanism of occlusion 
via eEF2 phosphorylation in Tsc2+/−, where some of the 
mRNAs and RPFs increased in Tsc2+/− mice appear to 
no longer respond to DHPG, consistent with the higher 
basal levels of eEF2 and the deficient eEF2 response fol-
lowing DHPG. Our work suggests a novel mechanism of 
translational dysregulation in Tsc2+/− and mGluR synap-
tic plasticity through signaling to ribosome elongation.
A combined Tsc2+/− and Fmr1−/y mouse rescues phe-
notypes in synaptic plasticity and contextual fear condi-
tioning in each other, yet the mechanism of this rescue 
paradigm has remained elusive. In Tsc2+/− and follow-
ing DHPG-mGluR signaling, FMRP binding targets have 
decreased TE from increased RNA levels; in Fmr1−/y, 
RNA levels of FMRP targets are instead decreased. Fur-
thermore, DHPG-induced phospho-eEF2 is deficient 
in Tsc2+/−, but enhanced in Fmr1−/y mice [14]. This 
bidirectional alteration of FMRP binding targets and 
mGluR5 signaling to elongation suggest mechanisms 
for the opposing changes in synaptic plasticity and res-
cue paradigm of the Tsc2+/−/Fmr1−/y mice. Because 
total FMRP protein levels are unchanged in Tsc2+/−, the 
dysregulation of FMRP binding targets may be through 
alternate pathways in transcription, mRNA stability, and/
or translation. Furthermore, mRNAs that are dysregu-
lated in Tsc2+/− are enriched for DHPG-mGluR-respon-
sive mRNAs and many of these overlapping mRNAs are 
FMRP binding targets. These results reveal a complex 
interaction between TSC2 and FMRP in steady state and 
mGluR regulation of distinct mRNA subclasses.
Limitations
We anticipated that loss of one copy of Tsc2 would 
result in widespread but perhaps subtle gene expres-
sion changes, consistent with other mouse models of 
neuropsychiatric disorders. As such, we used a FDR 
p-adjusted cutoff of 0.1 for the genotype comparison. 
One limitation of the interpretation of our ribosome 
profiling results is that we identified altered signaling to 
ribosome movement in Tsc2+/− and following mGluR-
LTD signaling. Thus, changes in ribosome density may 
not a priori reflect changes in protein synthesis. Multiple 
mouse models of autism have altered mGluR-LTD signal-
ing, but evidence of altered mGluR-LTD in humans with 
autism has yet to be established. For Figs.  1 and 5, we 
utilized hippocampal slices prepared from 72 mice for a 
sample size of three per group, a standard practice in the 
ribosome profiling and RNA-seq field. Sequencing exper-
iments with a sample size of 3 are limited by low power, 
and to reach a power of > 0.8 would require a sample 
size of 30 libraries from over 600 littermate mice, which 
is prohibitive in cost for animals and reagents. The low 
power indicates that our datasets have a high probabil-
ity of Type II errors (false negatives), and thus we would 
be unlikely to detect a genotype effect. This caveat, how-
ever, does not change the conclusions of our study. In any 
event, our findings need to be replicated in other studies.
Conclusions
By performing RNA-seq and ribosome profiling on a 
Tsc2+/− mouse model and following induction of mGluR-
LTD, we identified changes in FMRP binding targets that 
suggest a molecular basis for bidirectional regulation of 
synaptic plasticity and behavior by TSC2 and FMRP. Our 
study also suggests that altered mGluR-regulated transla-
tion elongation contributes to impaired synaptic plastic-
ity in Tsc2+/− mice.
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